Cartesian Therapeutics, Inc. (RNAC)

Cartesian Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	47.94	26	110.78	85.08
Revenue Growth (YoY)	-62.40%	-76.53%	30.21%	-
Cost of Revenue	49.83	65.64	72.38	68.74
Gross Profit	-1.89	-39.64	38.4	16.34
Selling, General & Admin	38.81	34.78	23.86	20.94
Operating Expenses	38.81	34.78	23.86	20.94
Operating Income	-40.7	-74.42	14.54	-4.6
Interest Expense	-	-2.83	-3.03	-2.84
Interest & Investment Income	5.87	4.96	2.07	0.04
Currency Exchange Gain (Loss)	-0	0.04	-0.02	-
Other Non Operating Income (Expenses)	-146	-136.16	21.21	-2.32
EBT Excluding Unusual Items	-180.83	-208.41	34.77	-9.72
Merger & Restructuring Charges	-12.1	-11.3	-	-
Asset Writedown	-0.7	-0.7	-	-
Other Unusual Items	-70.2	-18.3	-	-
Pretax Income	-263.83	-238.71	34.77	-9.72
Income Tax Expense	-19	-19	-0.61	15.97
Net Income	-244.83	-219.71	35.38	-25.69
Preferred Dividends & Other Adjustments	37.55	37.55	-	-
Net Income to Common	-282.38	-257.26	35.38	-25.69
Shares Outstanding (Basic)	12	5	5	4
Shares Outstanding (Diluted)	12	5	5	4
Shares Change (YoY)	-	6.33%	27.59%	-
EPS (Basic)	-23.06	-49.76	7.33	-6.74
EPS (Diluted)	-23.08	-49.80	2.98	-6.74
Free Cash Flow	-48.41	-51.37	-32.83	-61.47
Free Cash Flow Per Share	-3.95	-9.93	-6.75	-16.13
Gross Margin	-3.95%	-152.42%	34.66%	19.21%
Operating Margin	-84.90%	-286.17%	13.12%	-5.40%
Profit Margin	-589.05%	-989.31%	31.94%	-30.19%
Free Cash Flow Margin	-100.98%	-197.53%	-29.64%	-72.25%
EBITDA	-39.76	-73.57	15.83	-3.35
EBITDA Margin	-82.94%	-282.93%	14.29%	-3.93%
D&A For EBITDA	0.94	0.84	1.29	1.25
EBIT	-40.7	-74.42	14.54	-4.6
EBIT Margin	-84.90%	-286.17%	13.12%	-5.40%

Source: S&P Capital IQ. Standard template. Financial Sources.